Kate Anderton

Kate Anderton is an R&D Project Manager at Greywolf Therapeutics, where responsibilities include supporting preclinical studies from H2L through IND-enabling studies since March 2020. Prior experience includes serving as a Scientific Editor at AZoNetwork, creating content for the medical and life sciences sector, and working as a Microbiology Intern at MICROBIOLOGICAL SOLUTIONS LIMITED and GSK, where microbiological assessments were conducted. Kate's academic background includes a Biomedical Science B.Sc. from Lancaster University, complemented by a summer program at Radboud Summer School in July 2022.